Tesamorelin
FDA-approved GHRH analog for HIV-associated lipodystrophy
Visão Geral
Tesamorelin is an FDA-approved GHRH analog specifically indicated for treatment of HIV-associated lipodystrophy (excess abdominal fat).
Key Information
Mecanismo
Stabilized GHRH analog that stimulates endogenous GH production, targeting visceral fat reduction.
Benefits
- FDA-approved
- Reduces visceral fat
- Targets HIV lipodystrophy
- Stimulates natural GH
Side Effects
- Injection site reactions
- Joint pain
- Mild edema
Contraindications
- Active cancer
- Pregnancy
- Disruption of hypothalamic-pituitary axis
Evidence Summary
FDA-approved based on Phase 3 trials showing visceral adipose tissue reduction in HIV lipodystrophy.
Research
FDA-approved based on Phase 3 trials showing significant reduction in visceral adipose tissue.
Ver InvestigaciónSafety
FDA-approved. Side effects include injection site reactions and joint pain.
Legal Status
FDA-approved as Egrifta for HIV lipodystrophy.
Write a Review
Rating Breakdown
Avaliações
Tesamorelin specifically targets visceral fat. Lost 3 inches off waist in 4 months. FDA-approved for HIV lipodystrophy but works for metabolic syndrome too. GH stimulation is natural and potent.
Tesamorelin works well for visceral fat reduction but the cost is very high. Better results than CJC-1295 for abdominal fat. If you can afford it and have stubborn visceral fat, this is the peptide.